Core Viewpoint - JiTai Technology, a leading AI-driven nanomedicine company, has completed a Series D financing round of 400 million RMB, aimed at accelerating its strategic initiatives in platform automation, product pipeline development, international collaboration, and talent acquisition [2][6]. Financing and Investment - The recent financing round was led by the Beijing Pharmaceutical and Health Industry Investment Fund and the Daxing District Industrial Investment Fund, contributing to a total funding exceeding 2 billion RMB (approximately 300 million USD) since the company's inception [2][6]. - JiTai Technology previously completed two financing rounds in February 2022, raising a total of 150 million USD, and a Series C round in June 2024, raising 100 million USD [5][6]. Company Overview - Founded in 2020, JiTai Technology focuses on AI-driven innovations in nanomaterials, specifically targeting drug delivery and discovery technologies to combat diseases and aging [3]. - The company was co-founded by prominent scientists, including Dr. Chen Hongmin and Dr. Lai Caida, and has developed three core AI platforms: AiLNP, AiRNA, and AiTEM [3]. Industry Position and Collaboration - JiTai Technology is recognized as one of the "Four Little Dragons" in AI pharmaceuticals, alongside Deep Intelligence, Crystal Technology, and InSilico Medicine, emphasizing a collaborative rather than competitive approach within the industry [4]. - The company has achieved breakthroughs in targeted delivery capabilities for key organs and cells, providing opportunities for treating various diseases, including tumors and neurodegenerative disorders [4]. Strategic Initiatives - The company has launched the Open CGT technology platform, which aims to address industry challenges in precise drug delivery and facilitate the development of breakthrough cell and gene therapies [6][7]. - The first project under this platform focuses on enabling Rui Zheng Gene to develop mRNA-LNP-based liver-targeted CRISPR gene editing therapies [7]. Future Outlook - JiTai Technology's CEO highlighted that cell and gene therapy (CGT) will be a pillar of China's biopharmaceutical industry, representing the next generation of drug development [8]. - The company aims to contribute significantly to the entire drug delivery process, facilitating the transition from early-stage pipelines to market-ready products [8].